Adventrx Pharmaceuticals, Inc.
Pharmaceutical firm reports loss of $0.04 per share
Published in Pharma Investments, Ventures and Law Weekly, May 15th, 2005
For the fourth quarter of 2004, Adventrx reported a net loss of $2.4 million, or $0.04 per share, compared with a net loss of $815,000, or $0.02 per share, for the fourth quarter of 2003. For the year ended December 31, 2004, net loss was $6.7 million, or $0.13 per share, compared with a net loss of $2.4 million, or $0.07 per share, for the same period in 2003.
"Our most significant accomplishment during the past year was hitting the primary clinical endpoint of response rate for our phase II metastatic colorectal cancer trial with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Akzo Nobel
Pharmaceutical firm publishes full-year 2004 figures under IFRS rules - Alnylam Pharmaceuticals, Inc.
Alliance formed for intellectual property for RNAi therapeutics - American Oriental Bioengineering, Inc.
Chinese pharmaceutical firm reports 53.2% increase in revenue - Andromed, Inc.
Diagnostics developer reports loss of $0.03 per share - Atrium Biotechnologies, Inc.
Biotech company raises $75 million - Avanir Pharmaceuticals
Pharmaceutical firm completes $17.1M sale of common stock - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
